A large-scale genome study uncovered IL31 as a key genetic contributor to prurigo nodularis, linking it to immune-regulatory ...

The Democratic mayoral hopeful promises free child care, a $30 minimum wage and a massive tax hike on the city’s corporations. But much is not within a mayor’s control.

Galderma’s Nemluvio (nemolizumab) has demonstrated sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, according to results from a long-term extension ...

The global prurigo nodularis market is surging due to rising prevalence, increased awareness, and treatment innovations. Key drivers include advanced biologic therapies like dupilumab, addressing ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...

A dermatologist discusses nemolizumab (Nemluvio). Get the facts on this new treatment for prurigo nodularis: how well it works and who might benefit.

Galderma’s nemolizumab has been shown to improve the core signs and symptoms of prurigo nodularis, according to phase 3 results published in JAMA Dermatology. The 24-week OLYMPIA 1 trial evaluated the ...

The global prurigo nodularis treatment market is poised for substantial growth, projected to reach a valuation of USD 693.3 million by 2023, according to a recent report by Future Market Insights. The ...

Prurigo nodularis is an extremely itchy skin condition. It causes a rash that often includes hard lumps called nodules. You might also hear it called nodular prurigo. Doctors don’t know exactly ...

The Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab-ilto) for the treatment of adults with prurigo nodularis.

"The U.S. FDA’s rapid approval of Nemluvio in prurigo nodularis is a first step in achieving its blockbuster platform potential and reinforces our leadership in therapeutic dermatology. We’re ...